One-step assay for quantification of neutralizing antibodies to biopharmaceuticals

Journal of Immunological Methods

Volumn 356, Issue 1-2, 2010, Pages 18-28

  Lallemand, Christophe ^a   Meritet, Jean Francois ^b   Blanchard, Brigitte ^a   Lebon, Pierre ^b   Tovey, Michael G ^a  

^a INSTITUT ANDRÉ LWOFF   (France)

^b Université René Descartes ^*  (France)

Author keywords

Cell based assays; Cytokines; Immunogenicity; Interferons; Neutralizing antibodies; Reporter gene

Indexed keywords

DOXYCYCLINE; FIREFLY LUCIFERASE; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RENILLA LUCIFERIN 2 MONOOXYGENASE; INTERFERON;

ACCURACY; ANTIBODY DETECTION; ANTIBODY ENGINEERING; ARTICLE; CELL ASSAY; CELL COUNT; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ENGINEERING; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOGENICITY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; REPORTER GENE; STANDARDIZATION; BLOOD; GENETIC PROCEDURES; IMMUNOLOGY; LUMINESCENCE; METHODOLOGY; TUMOR CELL LINE;

HEPATITIS C VIRUS; RENILLA LUCIFERASE;

ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; GENES, REPORTER; GENETIC TECHNIQUES; HUMANS; INTERFERONS; LUMINESCENT MEASUREMENTS;

EID: 77951626931     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.03.003     Document Type: Article

References (24)

1. Aarden L., Ruuls S.R., Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 2008, 20:431.
2. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003, 348:601.
3. Baumann A. Nonclinical development of biopharmaceuticals. Drug Discov. Today 2009, 14:1112.
4. Benoit P., Maguire D., Plavec I., Kocher H., Tovey M., Meyer F. A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor. J. Immunol. 1993, 150:707.
5. Bertolotto A. Implications of neutralising antibodies on therapeutic efficacy. J. Neurol. Sci. 2009, 277(Suppl 1):S29.
6. Bertolotto A., Sala A., Caldano M., Capobianco M., Malucchi S., Marnetto F., Gilli F. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J. Immunol. Methods 2007, 321:19.
7. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002, 346:469.
8. Deisenhammer F., Schellekens H., Bertolotto A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J. Neurol. 2004, 251(Suppl 2):II31.
9. Grossberg S.E., Kawade Y., Kohase M., Klein J.P. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res. 2001, 21:743.
10. Grossberg S.E., Kawade Y., Kohase M., Yokoyama H., Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J. Interferon Cytokine Res. 2001, 21:729.
11. Grossberg S.E., Kawade Y., Grossberg L.D. The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels. J. Interferon Cytokine Res. 2009, 29:93.
12. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., Richards S.M., Rup B., Shores E., Swanson S.J., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 2007, 321:1.
13. Jorns C., Holzinger D., Thimme R., Spangenberg H.C., Weidmann M., Rasenack J., Blum H.E., Haller O., Kochs G. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha. J. Med. Virol. 2006, 78:74.
14. Kappos L., Clanet M., Sandberg-Wollheim M., Radue E.W., Hartung H.P., Hohlfeld R., Xu J., Bennett D., Sandrock A., Goelz S. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005, 65:40.
15. Kiladjian J.J., Chomienne C., Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008, 22:1990.
16. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S.J., Taniguchi G., Zuckerman L.A., Stebbins C.C., Mire-Sluis A. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1.
17. Lallemand C., Meritet J.F., Erickson R., Grossberg S.E., Roullet E., Lyon-Caen O., Lebon P., Tovey M.G. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J. Interferon Cytokine Res. 2008, 28:393.
18. Lam R., Farrell R., Aziz T., Gibbs E., Giovannoni G., Grossberg S., Oger J. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J. Immunol. Methods 2008, 336:113.
19. Leroy V., Baud M., de Traversay C., Maynard-Muet M., Lebon P., Zarski J.P. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J. Hepatol. 1998, 28:375.
20. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., Nyberg L.M., Lee W.M., Ghalib R.H., Schiff E.R., Galati J.S., Bacon B.R., Davis M.N., Mukhopadhyay P., Koury K., Noviello S., Pedicone L.D., Brass C.A., Albrecht J.K., Sulkowski M.S. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009, 361:580.
21. Meager A. Measurement of cytokines by bioassays: theory and application. Methods 2006, 38:237.
22. Moore M., Meager A., Wadhwa M., Burns C. Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. J. Pharm. Biomed. Anal. 2009, 49:534.
23. Neumann T.A., Foote M. Megakaryocyte growth and development factor (MGDF): an Mpl ligand and cytokine that regulates thrombopoiesis. Cytokines Cell. Mol. Ther. 2000, 6:47.
24. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 2009, 68:1739.